@article{d4b7aad0a105433b904ff59c30ba356a,
title = "Midlife vascular risk factors and midlife cognitive status in relation to prevalence of mild cognitive impairment and dementia in later life: The Atherosclerosis Risk in Communities Study",
abstract = "Introduction: The interplay between midlife vascular risk factors and midlife cognitive function with later life mild cognitive impairment (MCI) and dementia (DEM) is not well understood. Methods: In the Atherosclerosis Risk in Communities Study, cardiovascular risk factors and cognition were assessed in midlife, ages 45–64 years. In 2011–2013, 20–25 years later, all consenting Atherosclerosis Risk in Communities participants underwent a cognitive and neurological evaluation and were given adjudicated diagnoses of cognitively normal, MCI, or DEM. Results: In 5995 participants with complete covariate data, midlife diabetes, hypertension, obesity, and hypercholesterolemia were associated with late-life MCI and DEM. Low midlife cognition function was also associated with greater likelihood of late-life MCI or DEM. Both midlife vascular risk factors and midlife cognitive function remained associated with later life MCI or DEM when both were in the model. Discussion: Later life MCI and DEM were independently associated with midlife vascular risk factors and midlife cognition.",
keywords = "APOE, Cognition, Dementia, Diabetes, Epidemiology, Hypertension, Mild cognitive impairment, Prevalence",
author = "Knopman, {David S.} and Gottesman, {Rebecca F.} and Sharrett, {A. Richey} and Tapia, {Amanda L.} and Sonia DavisThomas and Windham, {B. Gwen} and Laura Coker and Schneider, {Andrea L.C.} and Alvaro Alonso and Josef Coresh and Albert, {Marilyn S.} and Mosley, {Thomas H.}",
note = "Funding Information: The Atherosclerosis Risk in Communities Study has been funded in whole or in part with Federal funds from the National Heart, Lung, and Blood Institute, National Institutes of Health, Department of Health and Human Services, under contract numbers. (HHSN268201700001I, HHSN268201700003I, HHSN268201700005I, HHSN268201700004I, and HHSN2682017000021). Neurocognitive data are collected by U01 2U01HL096812, 2U01HL096814, 2U01HL096899, 2U01HL096902, and 2U01HL096917 from the NIH (NHLBI, NINDS, NIA, and NIDCD), and with previous brain MRI examinations funded by R01-HL70825 from the NHLBI. The authors thank the staff and participants of the ARIC study for their important contributions., The funding sources had no role in the in study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the article for publication., The authors thank the staff and participants of the ARIC study for their important contributions. The authors would also acknowledge the contributions of Ola Selnes PhD and Guy McKhann MD, who participated in the dementia adjudication panel., Disclosures: D.S.K. serves on a Data Safety Monitoring Board for the DIAN study, is an investigator in clinical trials sponsored by Lilly Pharmaceuticals, Biogen, and the Alzheimer's Treatment and Research Institute at the University of Southern California; and receives research support from the NIH. R.F.G. is an Associate Editor for the journal Neurology and receives research support from the NIH. B.G.W. is an investigator in a clinical trial sponsored by ACADIA Pharmaceuticals. All the other authors report no conflict of interest. Funding Information: The Atherosclerosis Risk in Communities Study has been funded in whole or in part with Federal funds from the National Heart, Lung, and Blood Institute, National Institutes of Health, Department of Health and Human Services, under contract numbers. (HHSN268201700001I, HHSN268201700003I, HHSN268201700005I, HHSN268201700004I, and HHSN2682017000021). Neurocognitive data are collected by U01 2U01HL096812, 2U01HL096814, 2U01HL096899, 2U01HL096902, and 2U01HL096917 from the NIH (NHLBI, NINDS, NIA, and NIDCD), and with previous brain MRI examinations funded by R01-HL70825 from the NHLBI. The authors thank the staff and participants of the ARIC study for their important contributions. Funding Information: Disclosures: D.S.K. serves on a Data Safety Monitoring Board for the DIAN study, is an investigator in clinical trials sponsored by Lilly Pharmaceuticals, Biogen, and the Alzheimer's Treatment and Research Institute at the University of Southern California; and receives research support from the NIH. R.F.G. is an Associate Editor for the journal Neurology and receives research support from the NIH. B.G.W. is an investigator in a clinical trial sponsored by ACADIA Pharmaceuticals. All the other authors report no conflict of interest. Publisher Copyright: {\textcopyright} 2018 the Alzheimer's Association",
year = "2018",
month = nov,
doi = "10.1016/j.jalz.2018.03.011",
language = "English (US)",
volume = "14",
pages = "1406--1415",
journal = "Alzheimer's and Dementia",
issn = "1552-5260",
publisher = "Elsevier Inc.",
number = "11",
}